Here are my impressions after talking with a company representative on 3-14-22:
THIS IS NOT A TRANSCRIPT. THESE ARE NOT QUOTES FROM A COMPANY REPRESENTATIVE. THESE ARE MY IMPRESSIONS BASED ON A DISCUSSION WITH A COMPANY REPRESENTATIVE COMBINED WITH MY PRIOR KNOWLEDGE/THOUGHTS OF NWBO.
Where is company headed
- A therapy viable for brain cancer and able to go after all solid tumor cancers that you can get a piece of
- 15 solid tumor cancers – lung, liver, prostate, ovarian, etc.
- Hopes to be a major player in all solid cancers over the coming years
Why journal with TLD
- A Very small placebo group
- Had to find matched set of outside comparators
- Long difficult trial and wants to get support of community
- Experienced individuals including 3rd parties are saying this is the best path to take
- Want to lay the groundwork for a very supportive environment
- They don’t see this as laying the groundwork for just DCVax-L for GBM, but for the entire pipeline
- These experienced individuals/3rd parties are guiding them on all aspects of this process
- Roughly 450 GBM trials have failed in the last 15 years and they don’t want to add to that statistic
- Do you want to hurry and rush out data or take the time to put your best foot forward. NWBO is going with the later.
- Gain acceptance of clinical community, maybe by impressive results or publication, that creates an environment that physicians know, start to utilize and believe in it
- DNDN was an example of not doing the work on the front end and what NWBO is trying to avoid
- This is a lot more than just TLD, but how the world looks at solid tumors on all levels
- All solid tumors, think what that means if you lay the correct foundation
Market conditions
- 50% of all biotechs are down 50% this year
- Share price is not an indicator of how well the company is doing
- Current market is horrific for biotechs
Fud
- Very careful in chain of custody
- SAP before data is locked
- Shorts have an easy job, but it is important to stick to the plan
- The most effective shorts are those that go from positive to negative
Current leadership
- It isn’t about the money
- Hell bent on crossing the finish line
- Two recent hires quit very nice careers because they believed in what NWBO was doing
- My impression was they took a leap of faith based on the TLD
- There has been multiple personal connections of people with GBM to the leadership team and the leadership team is also frustrated and they want to get this across the finish line
Are we within a reasonable time frame for publication considering the circumstances?
- My impression was the company doesn’t believe it is unreasonable at this juncture
- they don’t think they are stretching the outer limits of a reasonable time frame
What Journal
- A world class journal
Manufacturing
- My impression was no q1/q2 certification
- Running comparability studies for flaskworks
- Not sure if they will get flaskworks certified for specials or just go straight for commercial certification
- Depends on demand, i.e. the volume of the specials program and how close they believe they are to commercial production. Why get flaskworks specials certified if you are close to commercialization or you don’t have the demand?
- My impression was they suspect flaskworks will be a simpler process and a better quality product
- I got the impression we are not delaying publication for manufacturing
Uplisting
- Not at the top of the priority list right now
- Needs to form a solid share price basis before this becomes a consideration
- The past price jumps to $2+ would not be considered a solid basis
- The last thing they want is to uplist and then struggle to stay on said exchange (shorts would love this)
- This is probably a priority in the future, but not right now
- If maybe they have a positive response to TLD/publication and they start thinking of approvals and the stock responds positively, uplisting would climb the ladder of importance
They understand the rules and regs
Bottom Line
- NWBO won’t do things to hype the stock
- Understand what you buy, understand what we are trying to do, we are working within solid tumor environment, enormous market… great advisors…only question is how long are you willing to wait
- Potentially dawn of a new age
